|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2009-5-13
|
|
pubmed:abstractText |
High-density lipoprotein (HDL) antiatherogenic functions seem to be diminished during inflammatory conditions such as rheumatoid arthritis (RA). The aim of this study was to investigate the effects of tumour necrosis factor (TNF) inhibition on the antioxidative capacity of HDL in RA.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antioxidants,
http://linkedlifedata.com/resource/pubmed/chemical/Antirheumatic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Aryldialkylphosphatase,
http://linkedlifedata.com/resource/pubmed/chemical/Biological Markers,
http://linkedlifedata.com/resource/pubmed/chemical/Carboxylic Ester Hydrolases,
http://linkedlifedata.com/resource/pubmed/chemical/Cholesterol, HDL,
http://linkedlifedata.com/resource/pubmed/chemical/Cholesterol, LDL,
http://linkedlifedata.com/resource/pubmed/chemical/Copper,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Necrosis Factor-alpha,
http://linkedlifedata.com/resource/pubmed/chemical/arylesterase,
http://linkedlifedata.com/resource/pubmed/chemical/infliximab
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
1468-2060
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
68
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
868-72
|
|
pubmed:meshHeading |
pubmed-meshheading:18635596-Aged,
pubmed-meshheading:18635596-Antibodies, Monoclonal,
pubmed-meshheading:18635596-Antioxidants,
pubmed-meshheading:18635596-Antirheumatic Agents,
pubmed-meshheading:18635596-Arthritis, Rheumatoid,
pubmed-meshheading:18635596-Aryldialkylphosphatase,
pubmed-meshheading:18635596-Biological Markers,
pubmed-meshheading:18635596-Blood Sedimentation,
pubmed-meshheading:18635596-Carboxylic Ester Hydrolases,
pubmed-meshheading:18635596-Cholesterol, HDL,
pubmed-meshheading:18635596-Cholesterol, LDL,
pubmed-meshheading:18635596-Chronic Disease,
pubmed-meshheading:18635596-Copper,
pubmed-meshheading:18635596-Drug Administration Schedule,
pubmed-meshheading:18635596-Female,
pubmed-meshheading:18635596-Follow-Up Studies,
pubmed-meshheading:18635596-Humans,
pubmed-meshheading:18635596-Male,
pubmed-meshheading:18635596-Middle Aged,
pubmed-meshheading:18635596-Oxidation-Reduction,
pubmed-meshheading:18635596-Statistics, Nonparametric,
pubmed-meshheading:18635596-Stimulation, Chemical,
pubmed-meshheading:18635596-Tumor Necrosis Factor-alpha
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Anti-inflammatory therapy with tumour necrosis factor alpha inhibitors improves high-density lipoprotein cholesterol antioxidative capacity in rheumatoid arthritis patients.
|
|
pubmed:affiliation |
Department of Rheumatology, Radboud University Nijmegen Medical Centre, The Netherlands. c.popa@reuma.umcn.nl
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't
|
